The race is on for medical treatment of NASH

Nonalcoholic steatohepatitis is the second leading indication for liver transplantation in the United States but there are currently no FDA-approved treatments available.Rohit Loomba, MD, MHSc, director of the NAFLD Research Center and director of hepatology, professor of medicine at the University of California, San Diego, told Healio Gastroenterology that in the next decade NASH will likely become the No. 1 indication for liver transplantation. The increase in the prevalence and incidence of obesity and type 2 diabetes will increase the burden of liver disease in the coming decades.In anRead More

Share on facebook
Share on twitter
Share on linkedin